40th Annual J.P. Morgan Health Care Conference (2022)

We no longer support this browser. Using a supported browser will provide a better experience.

Close browser message

The 40th Annual Health Care Conference will take place virtually on January 10-13, 2022.

This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

40th Annual J.P. Morgan Health Care Conference (1)

Jamie Dimon
Chairman and Chief Executive Officer,
JPMorgan Chase & Co.

Full Bio

40th Annual J.P. Morgan Health Care Conference (2)

Jessica Fye
Managing Director, Equity Research - Biotech,
J.P. Morgan

Full Bio

40th Annual J.P. Morgan Health Care Conference (3)

Catherine Pollard
Director of Tech Policy, NHSX

Full Bio

Jamie Dimon is Chairman of the Board and Chief Executive Officer of JPMorgan Chase & Co., a global financial services firm with assets of $2.5 trillion and operations worldwide. The firm is a leader in investment banking, financial services for consumers, small business, commercial banking, financial transaction processing and asset management. Dimon became CEO on January 1, 2006 and one year later also became Chairman of the Board. He was named President and Chief Operating Officer upon the company’s merger with Bank One Corporation on July 1, 2004. Dimon joined Bank One as Chairman and CEO in 2000. Dimon began his career at American Express Company. Next, he served as Chief Financial Officer and then President at Commercial Credit, which made numerous acquisitions and divestitures, including acquiring Prim-erica Corporation in 1987 and The Travelers Corporation in 1993. Dimon served as President and Chief Operating Officer of Travelers from 1990 through 1998 while concurrently serving as Chief Operating Officer of its Smith Barney Inc. subsidiary before becoming co-Chairman and Co-CEO of the combined brokerage following the 1997 merger of Smith Barney and Salomon Brothers. In 1998, Dimon was named President of Citigroup Inc., the global financial services company formed by the combination of Travelers Group and Citicorp. Dimon earned his bachelors degree from Tufts University and holds an M.B.A. from Harvard Business School. He serves on the boards of directors of a number of non-profit institutions including the Clearing House and Harvard Business School. Additionally, he is the Chairman of the Business Roundtable and serves on the executive committee of the Business Council and the Partnership for New York City, and is a member of the Financial Services Forum, Financial Services Roundtable and Council on Foreign Relations.

Jessica Fye is a Managing Director and Senior Analyst covering the U.S. SMid Cap Biotechnology sector with past coverage including Major and Specialty Pharmaceuticals. She has ranked in the top 3 in Mid- & Small-Cap Biotech by Institutional Investor, in addition to being recognized for multiple years as Runner-Up. Prior to that, she was a member of J.P. Morgan’s Institutional Investor-ranked Pharmaceuticals team. Before joining J.P. Morgan in 2008, Jessica worked in equity research at Bank of America focused on U.S. and European Major Pharma. She holds a BA in Business Economics from Brown University.

(Video) EQRx Presents at J.P. Morgan 40th Annual Healthcare Conference 2022

Catherine is the Director of Tech Policy at NHSX, having joined NHSX in April 2020 as the Director of the Centre for Improving Data Collaboration. The Centre, which she continues to lead, supports better data-driven partnerships between the NHS and industry, ensuring these promote patient and public benefit. During COVID-19, Catherine also led NHSX efforts to use technology to accelerate the integration of health and social care. Prior to joining NHSX, she was the Executive Programme Director for the Cambridgeshire & Peterborough STP, Director of Strategy at UCLH and a policy director at NHS Improvement. Catherine is inspired by how digital and data together can promote independence and person-centred care while addressing the multifaceted workforce challenges across health and care.

40th Annual J.P. Morgan Health Care Conference (4)

Chris Wigley
Chief Executive Officer, Genomics England

Full Bio

Prior to joining Genomics England, Chris was COO at QuantumBlack, a bespoke machine learning and AI technology company, and a Partner at McKinsey working on technology strategy topics. He also previously worked for the UK Foreign Office (Counter Terrorism Policy Department), and at the BBC. He has held board roles at the New Entrepreneurs Foundation, Entrepreneur First and Magic Breakfast.

40th Annual J.P. Morgan Health Care Conference (5)

Lord David Prior
Chair, NHS England

Full Bio

David has served as Chair of NHS England since 2018. He is inspired by the vision to bring together our growing understanding of human biology, artificial intelligence and behavioural science to develop a precision, personalised public health system whose primary goal is to prevent disease.Lord Prior was educated at Cambridge University and subsequently qualified as a barrister. He trained in finance at Lehman Brothers and Lazard Freres in New York before holding a number of senior positions within the industrial sector, including British Steel, where he was Commercial Director. He was elected MP for North Norfolk in 1997. He served as Chairman of Norfolk and Norwich University Hospitals NHS Foundation Trust from 2002-12 before becoming Chairman of the Care Quality Commission. In 2015, he was appointed Parliamentary Under Secretary of State for Health and created a Life Peer. In December 2016, he was appointed as Parliamentary Under Secretary of State at the Department of Business, Energy and Industrial Strategy, with specific responsibility for developing industrial strategy. He stepped down from this role in December 2017 to become Chairman of University College London Hospitals. He is deputy Chairman at Lazard.

40th Annual J.P. Morgan Health Care Conference (6)

Dan Mendelson
CEO, Morgan Health

Full Bio

Dan Mendelson is the Chief Executive Officer of Morgan Health at JPMorgan Chase & Co.Mendelson oversees a business unit at JPMorgan Chase focused on accelerating the delivery of new care models that improve the quality, equity and affordability of employer-sponsored healthcare.Mendelson was previously Founder and CEO of Avalere Health, a healthcare advisory company based in Washington, D.C. He also served as Operating Partner at Welsh Carson, a private equity firm. Before founding Avalere, Mendelson served as associate director for Health at the Office of Management and Budget in the Clinton White House. Mendelson currently serves on the boards of Vera Whole Health and Champions Oncology (CSBR). He is also an adjunct professor at the Georgetown University McDonough School of Business. He previously served on the boards of Coventry Healthcare, HMS Holdings, Pharmerica, Partners in Primary Care, Centrexion, and Audacious Inquiry. Mendelson holds a Bachelor of Arts (BA) from Oberlin College, and a Master of Public Policy (MPP) from the Kennedy School of Government at Harvard University.

40th Annual J.P. Morgan Health Care Conference (7)

Dr. Mark McClellan

Full Bio

Mark McClellan, MD, PhD, is Director and Robert J. Margolis, M.D., Professor of Business, Medicine and Policy at the Margolis Center for Health Policy at Duke University. He is a physician-economist who focuses on quality and value in health care, including payment reform, real-world evidence and more effective drug and device innovation. Dr. McClellan is at the center of the nation’s efforts to combat the pandemic and the author of a roadmap that details the steps needed for a comprehensive COVID-19 response and safe reopening of our country. He is former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. Dr. McClellan is an independent director on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ; co-chairs the Guiding Committee for the Health Care Payment Learning and Action Network; and serves as an advisor for Arsenal Capital Group, Blackstone Life Sciences, and MITRE.

(Video) LAVA Therapeutics Presentation || 40th Annual J.P. Morgan Healthcare Conference 2022

40th Annual J.P. Morgan Health Care Conference (8)

Andrew Bindman
MD, EVP and Chief Medical Officer,
Kaiser Permanente

Full Bio

Andrew Bindman, MD, is executive vice president and chief medical officer for Kaiser Permanente. He is responsible for driving superior quality and equitable health outcomes through the integration of quality innovation, care delivery, and research in collaboration with the Permanente Medical Groups. He is also Kaiser Permanente’s executive sponsor for the Kaiser Permanente Bernard J. Tyson School of Medicine. Dr. Bindman previously spent more than 30 years at the University of California, San Francisco where he practiced and taught clinical medicine while conducting research in health access and outcomes that resulted in more than 180 published scientific articles. A noted policy expert, he has held advisory and leadership roles for the U.S. House Energy and Commerce Committee, the U.S. Department of Health and Human Services, the Healthy California for All Commission, and the Agency for Healthcare Research and Quality. Dr. Bindman is a graduate of Harvard College and the Mount Sinai School of Medicine. A board-certified general internist, he completed his residency in internal medicine at UCSF and was a Robert Wood Johnson Foundation Clinical Scholar at Stanford University. He was elected to the National Academy of Medicine in 2015, where he currently serves on the board for health care services and chairs the workshops on diagnostic excellence. In 2021, he was elected to the Association of American Physicians in recognition for his notable contributions to advancing scientific and practical medicine.

40th Annual J.P. Morgan Health Care Conference (9)

Chiquita Brooks-LaSure
Centers for Medicare and Medicaid Services

Full Bio

Chiquita Brooks-LaSure is the Administrator for the Centers for Medicare and Medicaid Services (CMS), where she will oversee programs including Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and the HealthCare.gov health insurance marketplace. A former policy official who played a key role in guiding the Affordable Care Act (ACA) through passage and implementation, Brooks-LaSure has decades of experience in the federal government, on Capitol Hill, and in the private sector. As deputy director for policy at the Center for Consumer Information and Insurance Oversight within the Centers for Medicare & Medicaid Services, and earlier at the Department of Health & Human Services as director of coverage policy, Brooks-LaSure led the agency’s implementation of ACA coverage and insurance reform policy provisions. Earlier in her career, Brooks-LaSure assisted House leaders in passing several health care laws, including the Medicare Improvements for Patients and Providers Act of 2008 and the ACA, as part of the Democratic staff for the U.S. House of Representatives’ Ways and Means Committee. Brooks-LaSure began her career as a program examiner and lead Medicaid analyst for the Office of Management and Budget, coordinating Medicaid policy development for the health financing branch. Her role included evaluating policy options and briefing White House and federal agency officials on policy recommendations with regard to the uninsured, Medicaid and the Children’s Health Insurance Program.

40th Annual J.P. Morgan Health Care Conference (10)

Bertha Coombs
CNBC Reporter

Full Bio

Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. Her health care coverage has focused on health care service companies, including health insurers, hospitals and pharmacies, as well as the growing impact of digital health technology on the health care industry, ranging from the explosion of telehealth in the wake of the COVID pandemic to the companies trying to change the way primary care is delivered. In nearly two decades at CNBC, she has also covered technology firms from the Nasdaq Marketsite, the energy markets from the former floor of the New York Mercantile Exchange, as well as reported on the fallout of the 2008 financial crisis, and issues such as the growing impact of Latinos in the U.S. economy, and the push to improve health equity in the wake of social unrest in 2020. Before joining CNBC, Coombs was a reporter and anchor for the pioneering streaming business network, Yahoo Finance Vision. Prior, she served as a reporter for ABC News One, substitute anchor for “World News Now” and “World News This Morning,” after local news reporting jobs in New York and Miami.Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.

40th Annual J.P. Morgan Health Care Conference (11)

Jean Hynes
CEO, Wellington Management

Full Bio

As the chief executive officer of Wellington Management Company LLP, Jean leads the firm in our mission to drive excellence for clients to positively impact millions of beneficiaries’ lives. In pursuit of that mission, she spends significant time meeting with clients globally as well as working to strengthen and support the firm’s people and capabilities. She also serves on a variety of internal management committees, including the executive, operating, and compensation committees. In addition, she is one of the firm’s three managing partners, who are responsible for governance of the Wellington Management partnership, and she is the portfolio manager of the Vanguard Healthcare Fund.Throughout her 30 years at the firm, Jean has been a member of Wellington’s Global Industry Research Group and previously has had a number of responsibilities including researching the pharmaceutical and biotechnology industries, serving as a health care portfolio manager for a number of long and long/short strategies, and leading the Health Care Sector Research Team.Jean joined Wellington Management upon her graduation from Wellesley College (1991), where she was awarded a BA in economics. Additionally, she holds the Chartered Financial Analyst designation and is a member of the CFA Institute and the CFA Society Boston. She is also a member of the Investment Committee at Wellesley College.

(Video) Innovaccer at the 40th Annual J.P. Morgan Health Care Conference

40th Annual J.P. Morgan Health Care Conference (12)

Saira Malik
CFA CIO, Head of Global Equities

Full Bio

Saira is Chief Investment Officer for Nuveen’s $400+ billion globalequity business. As chair of the Equities Investment Council (EIC) and amember of the Global Investment Committee (GIC), Saira oversees thestrategic direction of equity investing for all of Nuveen. She also hasoversight responsibility for equity portfolio management, research, andtrading across the firm’s actively managed, quantitative, index, andtarget date strategies. In addition, Saira is the lead portfolio manager forthe $120+ billion CREF Stock strategy and a listed portfolio manager forthe $30+ billion CREF Growth and $20+ billion CREF Global Equitiesstrategies. She also serves as the sole manager of a $5 billion globalequity portfolio.Since joining the firm in 2003, Saira has held a variety of positions. Priorto being named global equities CIO, she was head of global equitiesportfolio management, and before that, head of global equities research.Previously, Saira was with JP Morgan Asset Management, where herroles included vice president/small cap growth portfolio manager andequity research analyst.Saira holds the CFA designation and graduated with a B.S. in economicsfrom California Polytechnic State University, San Luis Obispo, and anM.S. in finance from the University of Wisconsin, Madison. A soughtafter source of market expertise and insight, she authors a weekly equitymarket commentary on behalf of Nuveen’s EIC and frequently appearson financial news networks such as CNBC, Bloomberg and Fox Business.Saira has been profiled in Kiplinger’s and Barron’s, which ranked heramong the top 100 most influential women in U.S. finance.

40th Annual J.P. Morgan Health Care Conference (13)

Lucy DeStefano
Global Head of Trading and Systematic Strategies

Full Bio

Lucy DeStefano joined Soros Fund Management in 2018 and is Global Head of Trading and Systematic Strategies. Prior to SFM she ran trading at Aptigon Capital, part of Citadel. She also ran trading at Pine River Capital, as well as traded at Morgan Stanley and Goldman Sachs. Lucy graduated AB History, Cum Laude from Princeton University and is a host family for Right to Dream, USA.

40th Annual J.P. Morgan Health Care Conference (14)

Julie Murphy
Health Care Sector Specialist on the J.P. Morgan Trading Desk

Full Bio

Julie Murphy is the U.S. Healthcare Sector Specialists on the J.P. Morgan Equities Sales & Trading Team. In her current role, she works closely with the J.P. Morgan Healthcare Research Team leveraging fundamental research and market insights to provide dynamic perspectives on the Healthcare Sector. Prior to joining J.P. Morgan in 2017, Julie worked in a similar capacity at Morgan Stanley. She began her career in Healthcare Equities on the Morgan Stanley Equity Research Team. Julie graduated from The College of The Holy Cross in 2011 where she majored in History with minors in Philosophy and Mathematics.

Jess Fye

Senior Analyst, U.S. Biotechnology J.P. Morgan Research

(Video) Crinetics presents at the 40th Annual J.P. Morgan Healthcare Conference

Jess Fye

Senior Analyst, U.S. Biotechnology J.P. Morgan Research

Jess Fye: As we think about the biotech industry and how it adapted to COVID-19, one of the key themes that comes to mind is the real resilience of these companies in changing their commercial model in response to the pandemic. So when the pandemic broke out, one of the things you couldn't do was interact with a physician face to face. This is especially important when it's a drug that physicians aren't already familiar with. These companies quickly adopted more virtual means of educating physicians around their product. I think some of these strategies that the company has developed in response to COVID are gonna remain in 2022 and beyond. They've just found multiple effective ways to engage with doctors that are, that are actually working. The biotech sector has underperformed this year. There could be a variety of explanations for that. The sector did see a lot of outperformance the prior year, benefiting from maybe a halo effect of the industry tackling COVID. As a result, we really think you need to apply a selective approach heading into next year to sift through the real winners and the companies with the best innovation. M&A in the biotech sector is always tough to call when it comes to timing, I think investors would always want to see more rather than less. You contrast that with a very kind of high access to capital right now. You may not always see that acquisition because the companies are able to afford to continue to invest in development on their own. We do still expect a high level of IPOs and new company formation. The access to capital for these companies has been somewhat unprecedented. Heading into 2022, we're seeing some major innovations in the industry. Most people who have followed this industry would say the rate of acceleration has really increased over of the past 10 years and the past 10 years before that. Some of the key themes would be cell therapy and gene therapy. Those really represent new toolboxes to tackle some of these diseases and you're seeing a lot of investment behind those approaches. But we're also seeing real advances in more traditional disease areas that are leveraging our better understanding of the genetic underpinnings of some of these diseases. The rate of innovation shows no signs of slowing and lots of signs of picking up, and I think that makes it a really exciting industry to cover.

Chris Schott

Senior Analyst, U.S Major and Specialist Pharmaceuticals J.P. Morgan Research

Chris Schott

Senior Analyst, U.S Major and Specialist Pharmaceutical

Chris Schott: Looking at the current situation with the pandemic, I know there’s a lot of concerns around the new variants and I think that has some real implications as we think about the vaccines and therapeutics as well as the longer-term implications for how the sector’s approaching drug development.First of all: vaccine capacity. There are literally billions of additional doses of the vaccine that will be available in 2022 versus what was available in 21. And that’s gonna allow a much greater percentage of the world’s population to be vaccinated. The second thing are boosters. As new variants emerge, you create a new vaccine. And what’s great about the new technology being used is you can develop these in three to four months. And then finally, and I think really underappreciated, are the oral antivirals. These are products that you'll literally take five days worth of pills. You reduce hospitalization rates by 90 percent, death rates by 100 percent. I think it's a game changer in terms of dealing with the pandemic. If I think about broader takeaways to the pandemic, I think we're gonna see a much more efficient, much more focused pharmaceutical sector. I'm kind of amazed at how much the industry was able to produce in only 18 months. Now applying that to other therapeutic areas, I think we can see faster study enrollment, more creative study design, and that's gonna bring drugs to market much faster in some situations than we've ever seen previously. Heading into 2022, the pharma sector right now trades at an all time low versus the S&P 500. And I think there's really two issues that are overhanging the group: one, drug price reform, and we'll get some clarity on that with the infrastructure bill. The second is this longer term patent cliff. We're much more optimistic than the street about the ability for the industry to navigate through this. If I think about the last patent cliff, it was 2010 through 12, it really was a cliff. This time around, we've got internal pipelines that are looking great, we've got a lot more external opportunities to access innovation than we had in the past. And we think about this more as a slow down in growth, as compared to a cliff. We can see an acceleration of M&A going forward. We think M&A increasingly is focused on innovation, and it leads you to more pharma-biotech collaborations and consolidation, again versus the large pharma consolidation of the past. I see innovation as really a core theme for the sector. We're still at levels that are two times what they were 5 or 10 years ago. On Alzheimer's, we had the first disease modifying Alzheimer's drug approved in 2021; it's a very controversial product. Going to 22 and 23, there’s at least three additional products that we think really build upon this approval. And then finally on obesity, two diabetes products are actually associated with profound weight loss, and we think this creates a whole new category where we actually medicalize obesity. It can be something that insurers actually pay for and really encourage what that means for both patients with these conditions as well as the industry in terms of having a lot more new product flow.

The J.P. Morgan Health Care Conference is for clients of the firm, by invitation only. Please reach out to your J.P. Morgan representative to inquire about an invitation.

Some company presentations will be available on their individual websites.

The agenda is made available only to confirmed attendees.

Yes; there are a limited number of press passes for the event.

Unless otherwise specified, conference webinars are on-the-record and open to registered members of the press.

in-person @jpmorgan Steve Gleason, former NFL player for the New Orleans Saints and founder of the Team Gleason Foundation, shares the importance of assistive technology. Learn More
Innovation in Pharma J.P. Morgan's senior pharmaceuticals analyst, Chris Schott, is optimistic about innovation in pharma. Learn More
Global Research Reports J.P. Morgan's Research team leverages cutting-edge technologies and innovative tools to bring clients industry-leading analysis and investment advice. Learn More

J.P. Morgan’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan name.

Cancel Proceed

(Video) Presentation at the 40th Annual J.P. Morgan Healthcare Conference (January 12, 2022)


Is JPM 2022 happening? ›

Health Care Conference. January 10 – 13, 2022 | Virtual. The 40th Annual Health Care Conference will take place virtually on January 10-13, 2022.

What is J.P. Morgan conference? ›

J.P. Morgan conferences bring together corporate leaders, financial sponsors and institutional investors to explore market and sector trends. J.P. Morgan conferences are by invitation only.

How many people attend J.P. Morgan Healthcare Conference? ›

This year's 40th Annual Conference welcomed more than 625 leading Healthcare companies from around the world ranging from emerging private and small-cap companies to Fortune 100 corporations along with more than 3,000 global investors.

Where is the J.P. Morgan health conference? ›

The J.P. Morgan 40th Annual Healthcare Conference will take place 10 – 13 January 2022 in San Francisco, CA, USA.

What is jpm2022? ›

(NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. JPMorgan Chase had $4.0 trillion in assets and $285.9 billion in stockholders' equity as of March 31, 2022.


1. Absci Founder & CEO Sean McClain Presents at the J.P. Morgan 40th Annual Healthcare Conference 2022
2. Black Diamond Therapeutics $BDTX 40th Annual J.P. Morgan Healthcare Conference
3. Biomea Fusion Presents at the 40th Annual J.P. Morgan Healthcare Conference
(Biomea Fusion )
4. BCRX presents at 40th Annual J P Morgan Healthcare Conference January 10th 2022 9:45 am eastern.
5. Abiomed Corporate Presentation - J.P. Morgan Healthcare Conference 2022
6. Seegene Presentation at the 40th J.P. Morgan Healthcare Conference
(Seegene 씨젠)

Top Articles

You might also like

Latest Posts

Article information

Author: Moshe Kshlerin

Last Updated: 09/13/2022

Views: 6096

Rating: 4.7 / 5 (57 voted)

Reviews: 88% of readers found this page helpful

Author information

Name: Moshe Kshlerin

Birthday: 1994-01-25

Address: Suite 609 315 Lupita Unions, Ronnieburgh, MI 62697

Phone: +2424755286529

Job: District Education Designer

Hobby: Yoga, Gunsmithing, Singing, 3D printing, Nordic skating, Soapmaking, Juggling

Introduction: My name is Moshe Kshlerin, I am a gleaming, attractive, outstanding, pleasant, delightful, outstanding, famous person who loves writing and wants to share my knowledge and understanding with you.